ESCLEROSE MÚLTIPLA - ABORDAGENS DIAGNÓSTICAS E TERAPÊUTICAS: UMA REVISÃO BIBLIOGRÁFICA
DOI:
https://doi.org/10.47820/recima21.v5i2.4950Palavras-chave:
Esclerose múltipla, Diagnóstico, Terapêutica, Terapias modificadoras da doença, NeuroimunologiaResumo
Introdução: A esclerose múltipla (EM) é uma doença progressiva do sistema nervoso central com crescente prevalência global, representando um desafio para pacientes e profissionais de saúde. Este estudo visa abordar as recentes estratégias diagnósticas e terapêuticas para melhorar o manejo da EM. Objetivo: Fornecer uma visão abrangente das abordagens diagnósticas e terapêuticas da EM. Métodos: Realizou-se uma revisão bibliográfica dos últimos 15 anos em bases de dados eletrônicas, utilizando critérios de inclusão específicos. Quinze artigos foram selecionados após avaliação de títulos e resumos. Resultados e Discussão: Destacou-se o aumento da incidência da EM globalmente e os avanços no diagnóstico, incluindo o papel da ressonância magnética e biomarcadores. Abordaram-se também as terapias convencionais e emergentes, enfatizando a importância da individualização do tratamento e da abordagem multidisciplinar. Conclusão: A pesquisa contínua e ensaios clínicos são essenciais para preencher lacunas de conhecimento. A abordagem centrada no paciente, combinada com avanços científicos, promete melhorar a qualidade de vida e os resultados clínicos na EM.
Downloads
Referências
BAR-OR, Amit et al. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs, v. 74, p. 659-674, 2014. DOI: https://doi.org/10.1007/s40265-014-0212-x
BROWNLEE, Wallace J. et al. Diagnosis of multiple sclerosis: progress and challenges. The Lancet, v. 389, n. 10076, p. 1336-1346, 2017. DOI: https://doi.org/10.1016/S0140-6736(16)30959-X
CLAVELOU, Pierre. Can we optimize our teams? Multidisciplinary care for multiple sclerosis. Expert Review of Neurotherapeutics, v. 13, n. sup 2, p. 39-44, 2013. DOI: https://doi.org/10.1586/14737175.2013.865873
COHEN, Jeffrey A. et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. The Lancet, v. 380, n. 9856, p. 1819-1828, 2012. DOI: https://doi.org/10.1016/S0140-6736(12)61769-3
COMABELLA, Manuel; MONTALBAN, Xavier. Body fluid biomarkers in multiple sclerosis. The Lancet Neurology, v. 13, n. 1, p. 113-126, 2014. DOI: https://doi.org/10.1016/S1474-4422(13)70233-3
DENNISON, Laura; MOSS-MORRIS, Rona; CHALDER, Trudie. A review of psychological correlates of adjustment in patients with multiple sclerosis. Clinical psychology review, v. 29, n. 2, p. 141-153, 2009. DOI: https://doi.org/10.1016/j.cpr.2008.12.001
DEVONSHIRE, V. et al. The Global Adherence Project (GAP): A multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis. European Journal of Neurology, v. 18, n. 1, p. 69-77, 2011. DOI: https://doi.org/10.1111/j.1468-1331.2010.03110.x
DOBSON, Ruth; GIOVANNONI, Gavin. Multiple sclerosis–a review. European journal of neurology, v. 26, n. 1, p. 27-40, 2019. DOI: https://doi.org/10.1111/ene.13819
EVANS, Charity et al. Adherence to disease‐modifying therapies for multiple sclerosis and subsequent hospitalizations. Pharmacoepidemiology and Drug Safety, v. 26, n. 6, p. 702-711, 2017. DOI: https://doi.org/10.1002/pds.4207
FEINSTEIN, Anthony et al. The link between multiple sclerosis and depression. Nature Reviews Neurology, v. 10, n. 9, p. 507-517, 2014. DOI: https://doi.org/10.1038/nrneurol.2014.139
FILIPPI, M.; PREZIOSA, P.; ROCCA, M. A. Magnetic resonance outcome measures in multiple sclerosis trials: time to rethink? Curr Opin Neurol., v. 29, n. 3, p. 254-259, 2016.
FILIPPI, Massimo et al. Magnetic resonance techniques in multiple sclerosis: the present and the future. Archives of neurology, v. 68, n. 12, p. 1514-1520, 2011. DOI: https://doi.org/10.1001/archneurol.2011.914
FILIPPI, Massimo et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. The Lancet Neurology, v. 15, n. 3, p. 292-303, 2016. DOI: https://doi.org/10.1016/S1474-4422(15)00393-2
GALLIEN, Philippe et al. Multidisciplinary management of multiple sclerosis symptoms. European Neurology, v. 72, n. Suppl. 1, p. 20-25, 2014. DOI: https://doi.org/10.1159/000367620
GIOVANNONI, Gavin et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New England Journal of Medicine, v. 362, n. 5, p. 416-426, 2010. DOI: https://doi.org/10.1056/NEJMoa0902533
GOLDENBERG, Marvin M. Multiple sclerosis review. Pharmacy and therapeutics, v. 37, n. 3, p. 175, 2012.
HAUSER, Stephen L. et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine, v. 376, n. 3, p. 221-234, 2017. DOI: https://doi.org/10.1056/NEJMoa1601277
HAUSER, Stephen L.; CREE, Bruce AC. Treatment of multiple sclerosis: a review. The American journal of medicine, v. 133, n. 12, p. 1380-1390. e2, 2020. DOI: https://doi.org/10.1016/j.amjmed.2020.05.049
KALINCIK, Tomas. Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review. Neuroepidemiology, v. 44, n. 4, p. 199-214, 2015. DOI: https://doi.org/10.1159/000382130
LERAY, Emmanuelle et al. Epidemiology of multiple sclerosis. Revue neurologique, v. 172, n. 1, p. 3-13, 2016. DOI: https://doi.org/10.1016/j.neurol.2015.10.006
LIBERATORE, G. et al. Predictors of effectiveness of multidisciplinary rehabilitation treatment on motor dysfunction in multiple sclerosis. Multiple Sclerosis Journal, v. 20, n. 7, p. 862-870, 2014. DOI: https://doi.org/10.1177/1352458513508834
LUBLIN, Fred D. et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology, v. 83, n. 3, p. 278-286, 2014.
MARRIE, Ruth Ann et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Multiple Sclerosis Journal, v. 21, n. 3, p. 305-317, 2015. DOI: https://doi.org/10.1177/1352458514564487
MCGINLEY, Marisa P.; GOLDSCHMIDT, Carolyn H.; RAE-GRANT, Alexander D. Diagnosis and treatment of multiple sclerosis: a review. Jama, v. 325, n. 8, p. 765-779, 2021. DOI: https://doi.org/10.1001/jama.2020.26858
MONTALBAN, Xavier et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine, v. 376, n. 3, p. 209-220, 2017. DOI: https://doi.org/10.1056/NEJMoa1606468
ONTANEDA, Daniel; FOX, Robert J.; CHATAWAY, Jeremy. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. The Lancet Neurology, v. 14, n. 2, p. 208-223, 2015. DOI: https://doi.org/10.1016/S1474-4422(14)70264-9
PAGNINI, Francesco et al. Symptom changes in multiple sclerosis following psychological interventions: a systematic review. BMC neurology, v. 14, n. 1, p. 1-9, 2014. DOI: https://doi.org/10.1186/s12883-014-0222-z
PAPEIX, Caroline et al. Evaluation of an integrated multidisciplinary approach in multiple sclerosis care: A prospective, randomized, controlled study. Multiple Sclerosis Journal–Experimental, Translational and Clinical, v. 1, p. 2055217315608864, 2015. DOI: https://doi.org/10.1177/2055217315608864
POLMAN, Chris H. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of neurology, v. 69, n. 2, p. 292-302, 2011. DOI: https://doi.org/10.1002/ana.22366
RIETBERG, Marc B. et al. Effects of multidisciplinary rehabilitation on chronic fatigue in multiple sclerosis: a randomized controlled trial. PloS one, v. 9, n. 9, p. e107710, 2014. DOI: https://doi.org/10.1371/journal.pone.0107710
RÍO, Jordi; COMABELLA, Manuel; MONTALBAN, Xavier. Multiple sclerosis: current treatment algorithms. Current opinion in neurology, v. 24, n. 3, p. 230-237, 2011. DOI: https://doi.org/10.1097/WCO.0b013e328346bf66
THOMPSON, Alan J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology, v. 17, n. 2, p. 162-173, 2018. DOI: https://doi.org/10.1016/S1474-4422(18)30168-6
TINTORE, Mar; VIDAL-JORDANA, Angela; SASTRE-GARRIGA, Jaume. Treatment of multiple sclerosis—success from bench to bedside. Nature Reviews Neurology, v. 15, n. 1, p. 53-58, 2019. DOI: https://doi.org/10.1038/s41582-018-0082-z
WALLIN, Mitchell T. et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology, v. 92, n. 10, p. e1029-e1040, 2019.
WATTJES, Mike P. et al. MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. The Lancet Neurology, v. 20, n. 8, p. 653-670, 2021. DOI: https://doi.org/10.1016/S1474-4422(21)00095-8
WATTJES, Mike P.; RAAB, Peter. Brain and spinal cord MRI in multiple sclerosis: an update. Neurology International Open, v. 1, n. 04, p. E294-E306, 2017 DOI: https://doi.org/10.1055/s-0043-118111
WILSKI, Maciej et al. Psychological factors associated with self‐management in multiple sclerosis. Acta Neurologica Scandinavica, v. 142, n. 1, p. 50-57, 2020. DOI: https://doi.org/10.1111/ane.13236
ZIEMSSEN, Tjalf et al. Optimizing treatment success in multiple sclerosis. Journal of neurology, v. 263, p. 1053-1065, 2016. DOI: https://doi.org/10.1007/s00415-015-7986-y
Downloads
Publicado
Licença
Copyright (c) 2024 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
